RXRX Stock Chart & Stats
$53.00
$0.00(0.00%)
―
--
Day’s Range― - ―
52-Week Range$49.00 - $130.00
Previous CloseN/A
VolumeN/A
Average Volume (3M)1.96K
Market Cap
$27.47B
Enterprise Value$1.04K
Total Cash (Recent Filing)$654.47M
Total Debt (Recent Filing)$72.38M
Price to Earnings (P/E)―
Beta-0.16
Next Earnings
Aug 11, 2026EPS Estimate
-4.2Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.20
Shares OutstandingN/A
10 Day Avg. Volume4,124
30 Day Avg. Volume1,958
Financial Highlights & Ratios
PEG Ratio0.19
Price to Book (P/B)1.62
Price to Sales (P/S)24.50
P/FCF Ratio-4.84
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
$129.13Price Target Upside― Downside
Rating ConsensusModerate Buy
Number of Analyst Covering5
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
RXRX FAQ
What was Recursion Pharmaceuticals, Inc’s price range in the past 12 months?
Recursion Pharmaceuticals, Inc lowest stock price was $49.00 and its highest was $130.00 in the past 12 months.
What is Recursion Pharmaceuticals, Inc’s market cap?
Recursion Pharmaceuticals, Inc’s market cap is $27.47B.
When is Recursion Pharmaceuticals, Inc’s upcoming earnings report date?
Recursion Pharmaceuticals, Inc’s upcoming earnings report date is Aug 11, 2026 which is in 16 days.
How were Recursion Pharmaceuticals, Inc’s earnings last quarter?
Recursion Pharmaceuticals, Inc released its earnings results on May 06, 2026. The company reported -$3.852 earnings per share for the quarter, beating the consensus estimate of -$4.64 by $0.788.
Is Recursion Pharmaceuticals, Inc overvalued?
According to Wall Street analysts Recursion Pharmaceuticals, Inc’s price is currently Undervalued.
Does Recursion Pharmaceuticals, Inc pay dividends?
Recursion Pharmaceuticals, Inc does not currently pay dividends.
What is Recursion Pharmaceuticals, Inc’s EPS estimate?
Recursion Pharmaceuticals, Inc’s EPS estimate is -4.2.
How many shares outstanding does Recursion Pharmaceuticals, Inc have?
Currently, no data Available
What happened to Recursion Pharmaceuticals, Inc’s price movement after its last earnings report?
Recursion Pharmaceuticals, Inc reported an EPS of -$3.852 in its last earnings report, beating expectations of -$4.64. Following the earnings report the stock price went down -4.839%.
Which hedge fund is a major shareholder of Recursion Pharmaceuticals, Inc?
Currently, no hedge funds are holding shares in MX:RXRX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Recursion Pharmaceuticals Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$129.13 (― Downside)
$129.13 (― Downside)
Blogger Sentiment
Bullish
MX:RXRX Sentiment 70%
Sector Average 65%
Sector Average 65%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-53.18%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
2.63%
Trailing 12-Months
Company Description
Recursion Pharmaceuticals, Inc
Recursion Pharmaceuticals, Inc. operates as a biotechnology firm currently in its clinical development phase. The company's mission is to revolutionize drug discovery by decoding biological processes, utilizing an integrated approach that combines technological innovations across biology, chemistry, automation, data science, and engineering. Their developmental pipeline features several clinical-stage compounds: REC-994, which is advancing through Phase IIa trials for cerebral cavernous malformation; REC-3599, currently in Phase I trials for GM2 gangliosidosis; REC-2282, aimed at treating neurofibromatosis type 2; and REC-4881, intended for familial adenomatous polyposis. Beyond these, Recursion maintains a comprehensive preclinical portfolio. This includes REC-3964 for Clostridium difficile colitis, REC-64917 targeting neural or systemic inflammation, and REC-65029 for HRD-negative ovarian cancer. Further preclinical candidates are REC-648918, designed to enhance anti-tumor immunity; REC-2029 for wnt-mutant hepatocellular carcinoma; REC-14221 for various solid and hematological malignancies; and REC-64151, focused on addressing immune checkpoint resistance in KRAS/STK11 mutant non-small cell lung cancer. The company has established strategic collaborations and agreements with partners such as Bayer AG, the University of Utah Research Foundation, the Ohio State Innovation Foundation, Chromaderm, Inc., and Takeda Pharmaceutical Company Limited. Recursion Pharmaceuticals, Inc. was founded in 2013 and is headquartered in Salt Lake City, Utah.
RXRX Stock 12 Month Forecast
Average Price Target
$129.13